Regeneron Pharmaceuticals, Inc., United States
Disclosure information not submitted.
6D-04 - Assessing Current Biomarker Testing Rates Leveraging Structured and Unstructured Real-World Data (RWD): A Case Study of Programmed Death-Ligand 1 (PD-L1) Testing Trends for Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Tuesday, August 26, 20251:45 PM - 1:50 PM ET
